Comprehensive review of liraglutide — the first once-daily GLP-1 receptor agonist — covering its pharmacology, clinical trial results, weight loss effects, and cardiovascular safety data.
Key findingComprehensive review of liraglutide — the first once-daily GLP-1 receptor agonist — covering its pharmacology, clinical trial results, weight loss eff
What the researchers found
Comprehensive review of liraglutide — the first once-daily GLP-1 receptor agonist — covering its pharmacology, clinical trial results, weight loss effects, and cardiovascular safety data.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
The American journal of managed care, 17(2 Suppl), S59-70
Citation
Bode, Bruce. (2011). Liraglutide: a review of the first once-daily GLP-1 receptor agonist.. The American journal of managed care, 17(2 Suppl), S59-70.